Orion Corporation: Managers’ transactions – Satu Ahomäki
ORION CORPORATION
MANAGERS’ TRANSACTIONS
4 August 2025 at 16:10 EEST
Orion Corporation: Managers’ transactions – Satu Ahomäki
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Satu Ahomäki
Position: Other senior manager
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 116614/10/19
____________________________________________
Transaction date: 2025-08-04
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 605 Unit price: 70.7 EUR
(2): Volume: 1600 Unit price: 70.7 EUR
Aggregated transactions (2):
Volume: 2205 Volume weighted average price: 70.7 EUR
____________________________________________
Transaction date: 2025-08-04
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 71 Unit price: 70.7 EUR
(2): Volume: 724 Unit price: 70.7 EUR
Aggregated transactions (2):
Volume: 795 Volume weighted average price: 70.7 EUR
Orion Corporation
| Liisa Hurme President and CEO | Mikko Kemppainen General Counsel |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.
